TL;DR — MitoQ is a ubiquinone bolted to a lipophilic cation that concentrates it inside mitochondria, where it mops up the reactive oxygen species that drive vascular aging. In a University of Colorado RCT, 20 mg/day for 6 weeks improved endothelial function by ~42% in older adults. Mechanistically elegant and human-tested for vascular function — but small trials, surrogate endpoints, and no outcome data. 10–20 mg/day.
What MitoQ does (and why it matters)
Excess mitochondrial reactive oxygen species (ROS) is a core mechanism of age-related vascular dysfunction. Ordinary antioxidants barely reach the mitochondrial inner membrane; MitoQ is engineered to accumulate there hundreds-fold, quenching ROS at the source. The translated payoff in humans so far is better endothelial function and lower arterial stiffness — the vascular phenotypes that track with aging.
Primary hallmarks targeted: Mitochondrial dysfunction · Altered intercellular communication
Mechanism — a mitochondria-targeted antioxidant
MitoQ links ubiquinone to a triphenylphosphonium (TPP⁺) cation; the mitochondrial membrane potential drives the whole molecule into the matrix side of the inner membrane, where it is recycled by the respiratory chain and neutralizes ROS. This targeting is what separates it from ordinary CoQ10 — same quinone chemistry, radically different distribution.
Evidence summary
| Study | Design | N | Duration | Key outcome | Tier |
|---|---|---|---|---|---|
| Rossman 2018 (PMID 29661838) | RCT, crossover | 20 | 6 wk | Brachial FMD +42%; lower aortic stiffness & oxidized LDL in older adults | B |
← Swipe for more columns →
Consensus: The mechanism is among the most rigorously worked out in the space, and the flagship human trial showed a large improvement in a validated vascular endpoint. But it is one small crossover study of a surrogate outcome; there are no hard-outcome trials, and MitoQ is expensive.
Where MitoQ disappoints
- Hard outcomes — there are no event trials; the case is a single small surrogate-endpoint study. - "It's just a better CoQ10" — for classic CoQ10 uses (statin myalgia, deficiency) regular ubiquinol is cheaper and better-studied; MitoQ's edge is mitochondrial targeting, not being "stronger CoQ10." - Exercise performance — some athletic-performance trials have been null; the endothelial story is the strong one.
What would change this grade. The tier is B because a rigorous mechanism plus one good human vascular-function RCT outweigh the absence of outcome data. It would rise with independent replication and any clinical-outcome signal, and fall if larger trials failed to reproduce the endothelial benefit.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 10–20 mg/day | The trial used 20 mg/d |
| Timing | Morning, with or without food | — |
| Duration | 6 weeks (vascular endpoints) | Effects build over weeks |
Monitoring
Where available, endothelial function (flow-mediated dilation) or arterial stiffness before/after; otherwise home blood pressure and, if you track it, oxidized-LDL. No routine labs required.
Safety, red flags, and contraindications
- Well tolerated at 20 mg/day in trials; GI upset is the main complaint.
- Long-term safety in humans is not established beyond short trials.
Do not self-start without clearance
- Pregnancy / breastfeeding — no safety data.
- On complex cardiac regimens — discuss before adding a novel mitochondrial agent.
Who should skip MitoQ
- People who just want CoQ10 benefits — use ubiquinol; it's cheaper and better-studied for those uses. - Anyone expecting proven longevity or event reduction — that evidence doesn't exist yet.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Urolithin A | Complementary mitochondrial-quality lever (mitophagyA specific form of autophagy that selectively removes damaged or dysfunctional mitochondria, replacing them with healthy ones. Full glossary →) | Mitochondrial stack |
| CoQ10 | Overlapping quinone chemistry — usually pick one role each | Mitochondrial stack |
| Omega-3 | Broader endothelial/vascular support | Cardiovascular stack |
Works against / redundant with: Running MitoQ and high-dose CoQ10 for the same purpose is largely redundant — they share the quinone mechanism. Choose based on goal (mitochondrial targeting vs. classic CoQ10 repletion).
Personal results template
My MitoQ results log
| Date | Week | Dose | Home SBP | FMD / stiffness (if available) | Notes |
|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | Baseline |
| YYYY-MM-DD | 6 | — | — | — | Endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: improved vascular measure or consistent BP reduction - Plateau: no change by 6 weeks → reconsider the cost - Adverse: GI upset → take with food or stop
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.